Phenomen Pharma

Phenomen Pharma is a German biotechnology company specializing in the discovery and development of small molecule inhibitors targeting the ubiquitin-proteasome system (UPS). The company's lead program focuses on Ubiquitin-specific protease 7 (USP7), an enzyme that plays a critical role in regulating the stability of tumor suppressors and oncogenes. By inhibiting USP7, Phenomen Pharma aims to restore natural cell death pathways in cancer cells, providing a novel approach to treating solid tumors and blood cancers. Currently in the pre-clinical stage, the company utilizes a structure-based drug design approach to optimize its pipeline of high-affinity compounds. The firm was founded as a spin-off from the German Cancer Research Center (DKFZ) to translate academic excellence into clinical oncology solutions.